Subfoveal Choroidal ThicknessT1500301.28 ± 60.00326.60 ± 50.19341.32 ± 86.580.034 a

; independent samples t-test,

0.009 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.462T1000302.90 ± 59.01336.17 ± 53.07339.94 ± 85.590.044 a

; independent samples t-test,

<0.0010.833a

; independent samples t-test,

T500307.96 ± 61.43336.60 ± 62.88338.26 ± 88.260.113 a

; independent samples t-test,

0.001 0.934a

; independent samples t-test,

SFCT309.65 ± 68.05330.10 ± 67.26347.94 ± 82.580.045 a

; independent samples t-test,

0.002 0.362a

; independent samples t-test,

N500290.15 ± 66.54321.03 ± 79.55335.91 ± 82.330.016 a

; independent samples t-test,

0.005 0.475a

; independent samples t-test,

N1000271.37 ± 69.27305.14 ± 76.60317.88 ± 83.000.016 a

; independent samples t-test,

<0.001 0.536a

; independent samples t-test,

N1500252.28 ± 73.36291.25 ± 90.60289.08 ± 74.310.026 <0.001 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.918a

; independent samples t-test,

Peripapillary Choroidal ThicknessNasal189.00 ± 64.81198.50 ± 53.20231.20 ± 62.090.063 0.311 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.308Superonasal187.15 ± 56.87202.10 ± 61.96217.11 ± 65.440.076 0.049 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.305Superotemporal187.46 ± 56.59196.42 ± 51.41220.58 ± 56.390.020 a

; independent samples t-test,

0.370 0.086a

; independent samples t-test,

Temporal177.37 ± 69.72198.39 ± 66.65216.85 ± 70.460.017 0.022 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.297a

; independent samples t-test,

Inferonasal176.84 ± 49.30188.53 ± 47.96193.29 ± 65.700.426 0.218 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.871Inferotemporal157.75 ± 48.45179.35 ± 53.40186.76 ± 62.770.066 0.004 d

; Wilcoxon test, P1; early postinfectious period of Covid -19 group vs. control group, P2; early vs. late postinfectious period of Covid-19, P3; late postinfectious period of Covid -19 group vs. control group.

0.666